Moderna company profile

MRNA · NASDAQ · USD

$223.37Change from previous close: −3.45%Absolute change: −$7.98

Close · November 13, 2026

Company profile

Moderna has 4,700 employees and is headquartered in Cambridge, United States.

Moderna, Inc., a biotechnology company with 4,700 employees, develops messenger RNA medicines for markets in the United States, Europe and other regions. Its respiratory vaccines include COVID, RSV and seasonal influenza products under the Spikevax and mRESVIA names, while its portfolio also covers latent virus vaccines against cytomegalovirus and Epstein-Barr virus, public health vaccines against Zika, Nipah and Mpox, oncology therapeutics such as intismeran autogene, and rare disease treatments for propionic and methylmalonic acidemia and cystic fibrosis. Its collaborators include Merck & Co., Vertex Pharmaceuticals, the Bill & Melinda Gates Foundation and OpenAI.

Moderna is headquartered in Cambridge, Massachusetts, and was founded in 2010. It changed its name from Moderna Therapeutics in August 2018. In the fiscal year ended December 2025, revenue was USD 1.9 billion, down 39.9% from the previous year, and the company posted a net loss of USD 2.8 billion. By region, the United States accounted for 61.7% of revenue, the rest of the world for 35.6% and Europe for 2.7%.

Company facts

Industry
Biotechnology
Headquarters
325 Binney Street, 02142, Cambridge
Employees
4,700
Chief executive
Stéphane Bancel
Founded
2010
Fiscal year
January - December
Listing
MRNA · NASDAQ
Currency
USD
ISIN
US60770K1079

Moderna and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
ModernaMRNAUnited States$90.38B4,700-80.8%—
Regeneron PharmaceuticalsREGNUnited States$98.84B15,41030.4%21.1
argenxARGXUnited States$60.37B1,86331.9%33.3
Vertex PharmaceuticalsVRTXUnited States$136.56B6,40037.8%34.7
BeOne MedicinesONCUnited States$47.58B12,00017.8%53.4
Royalty PharmaRPRXUnited States$39.85B10064.4%45.3

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Moderna with its competitors